louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03118557: Pilates Pelvic Floor Strengthening Program to Improve Urinary Incontinence
Official title: HLP-16-003H: Does a Twice Weekly, 12-week Pilates Pelvic Floor Strengthening Program Improve Short- and Long-term Measures of Stress Urinary Incontinence Symptoms in Women Ages 45-70 Years of Age.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress Urinary Incontinence
Keywords: pelvic floor
strengthening
Stress
urinary
incontinence
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-04-18
Enrollment: 27
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Does a twice weekly, 12-week Pilates pelvic floor strengthening program improve short- and long-term measures of stress urinary incontinence symptoms in women ages 45-70 years of age?


Eligibility criteria: Inclusion Criteria:

1. Age 45-70 years of age.
2. Able to provide informed consent.
3. Able to lower and rise from the floor safely and independently.
4. Anticipated to be able to attend at least 9 of the first 12 classes (75%) in weeks 1-6.
5. Anticipated to be able to attend at least 9 of the final 12 classes (75%) in weeks 7-12.
6. Score of 6+ on ICIQ-UI Short Form.

Exclusion Criteria:

1. Pregnancy
2. Unable to speak and comprehend English
3. Chronic neurologic condition (e.g., Parkinson's or Multiple Sclerosis) that impacts bladder function.

Primary outcomes:
measure: Change in score on International Consultation on Incontinence (ICIQ-UI Short Form)
timeFrame: Baseline, 12 weeks
Secondary outcomes:
measure: Change in score on Medical, Epidemiological, Social Aging (MESA) Urinary Incontinence Questionnaire
timeFrame: Baseline, 12 weeks
measure: Change in score on Linear Analogue Self Assessment (LASA)
timeFrame: Baseline, 12 weeks
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Deborah J Rhodes
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03500757: Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation
Official title: Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation as an Adjunct to Standard Flat Panel Display
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Percutaneous Tumor Ablation
Keywords: HoloLens
3D holographic guidance
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2018-04-18
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This device evaluation will include patients undergoing percutaneous thermal ablation of solid liver tumors at Cleveland Clinic as clinically indicated in the standard of care.

Brief summary: Medical images used to guide treatment of tumor(s) are presently displayed on flat-panel monitors (like screens used with computers). This protocol will evaluate, using a new headset to view the images in true 3D ("360 degrees"), while using standard flat panel monitors as usual (in accordance with standard of care). The headset is combined with a mini-global positioning system (GPS)-like system to help navigate to treat tumor(s). This evaluation is to show that the headset has potential to provide guidance and navigation information that can improve the treatment of tumor(s) with heat.

Detailed description: This protocol will clinically evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors to ultimately overcome limitations of displaying images on 2D flat-panel monitors ("flat screens"). 3D Holographic percutaneous ablation (3D HPA) provides real-time, 360° visualization for guidance and navigation of tracked interventional instruments augmented to the operative site. In this preliminary protocol, 3D HPA will be evaluated as an adjunct to flat-screen display of conventional images used for guidance (ultrasound, fluoroscopy, CT), in accordance with standard of care.

Eligibility criteria: Inclusion Criteria:

* Not pregnant
* Willing and able to give informed consent prior to enrollment. This includes media release form.
* Has met all criteria to undergo percutaneous tumor ablation.

Exclusion Criteria:

* Not willing or able to give informed consent
* Patients with pacemakers or automated implantable cardioverter defibrillator (AICDs).

Primary outcomes:
measure: Standard System Usability Score on a Likert Scale
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Cleveland Clinic, Case Comprehensive Cancer Center
name: Charles Martin III, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02872857: Subarachnoid Hemorrhage Recovery And Galantamine
Official title: A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Subarachnoid Hemorrhage
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2016-08-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.


Eligibility criteria: Inclusion Criteria:

* Spontaneous subarachnoid hemorrhage
* Presentation to hospital within 72 hours of symptoms
* Fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography (CT) scan
* Hunt and Hess grade 1-5 at time of randomization
* Presence of a cerebral aneurysm on computed tomographic angiography (CTA) or Angiogram for which clipping or coiling is possible
* Ability to obtain medication within 36 hours of presentation

Exclusion Criteria:

* subarachnoid hemorrhage (SAH) due to causes other than aneurysm rupture (trauma, arteriovenous malformation (AVM), mycotic aneurysms, Moyamoya)
* Pre-existing disability with modified Rankin Scale (mRS) score ≥2,
* Renal disease as defined by creatinine clearance less than 9 milliliters/min
* History of severe hepatic impairment (Child-Pugh score of 10-15)
* History of chronic obstructive pulmonary disease (COPD) or asthma
* History of dementia
* Co-morbid conditions likely to complicate therapy, including clinically significant arrhythmia, acquired immune deficiency syndrome (AIDS), autoimmune disease, malignancy, and expected mortality within 72 hours
* Expected mortality within 72 hours as determined by PI, treating neurointensivist and neurosurgeon. (Clinically manifested by no attempt at securing aneurysm)
* Females who are pregnant.

Primary outcomes:
measure: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug
timeFrame: 90 days
measure: Mortality
timeFrame: 90 days
measure: Modified Rankin Score
timeFrame: 90 days
Secondary outcomes:
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: baseline (in hospital)
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: 90 days
measure: EuroQOL Score as Assessed by a Visual Analogue Scale (VAS)
timeFrame: 90 days
Other outcomes:
Locations:
city: Houston
country: United States
facility: Houston Methodist Hospital Texas Medical Center
state: Texas
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Huimahn Choi, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05322057: Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease
Official title: Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease - a Prospective Nationwide Multicentre Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Crohn Disease
Fistula Perianal
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 14 patients with Crohn's disease and complex fistula got enrolled in this study.

Brief summary: The use of mesenchymal stem cells is considered a novel and promising therapeutic option for patients with perianal fistulizing Crohn's disease. However, due to limited clinical data, this multicentre, nationwide study aimed to assess its clinical efficacy in closing complex anal fistula.

Detailed description: Fifteen applications in 14 patients (3 male, 11 female) with complex anal fistulas treated in three tertiary hospitals in Austria were included between October 2018 and April 2021. Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells (Cx601 - Darvadstrocel, Alofisel®) was performed in each patient. Closure of the external fistula opening without secretion by finger compression was defined as success.

Eligibility criteria: Inclusion Criteria:

* patients aged 18 and older who had a non-active or mildly active luminal CD with complex fistula with a maximum of two internal and three external fistulas

Exclusion Criteria:

* rectovaginal fistulas
* rectal and/or anal stenosis
* active proctitis
* diverting stomas
* an abscess (\<2cm) that was not drained at the fistula preperation visit

Primary outcomes:
measure: Fistula Closure
timeFrame: 1 year
Secondary outcomes:
measure: Evaluation of perianal disease
timeFrame: 1 year
measure: Evaluation of Crohn's disease
timeFrame: 1 year
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna, Head of Pelvic Floor Surgery
name: Stefan Riss, Prof.MD
role: STUDY_CHAIR
References:
Clinical trial NCT03190148: Glucose Metabolism in Pregnant Women With a History of Bariatric Surgery, as Well as Three to Six Months After Delivery.
Official title: Explorative Study: Diagnosis and Medical Care of Disturbances of Glucose Metabolism in Pregnant Women With a History of Bariatric Surgery, Normal Weight and Obese Pregnant Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bariatric Surgery Candidate
Pregnancy Complications
Pregnancy Related
Glucose Metabolism Disorders
Keywords: GLP-1
Ectopic Lipids
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2017-06-16
Enrollment: 64
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this study glucose metabolism of pregnant women with a history of bariatric surgery, obese pregnant women and normal weight pregnant women was investigated. Three to six months after delivery the assessment of Glucose metabolism was repeated and the amount of ectopic lipids in the liver, heart and muscle was measured.

Detailed description: In this study pregnant women with a history of bariatric surgery, normal weight and obese pregnant women were invited to participate. Between the 24th and the 28th week of pregnancy an oral glucose tolerance test (OGTT), as well as an intravenous glucose tolerance test (IVGTT) was conducted. Three to six months after delivery the examinations were repeated. In addition the ectopic lipid content in the liver, heart and the muscle was measured with 1H-magnetic resonance spectroscopy and imaging three to six months post partum. The aim of this study was to compare the glucose metabolism during pregnancy between the three groups as well as to investigate the changes three to six months after delivery.

Eligibility criteria: Inclusion Criteria:

* pregnant women with a history of RYGB Operation
* normal weight pregnant women
* obese pregnant women

Exclusion Criteria:

* infectious diseases such as Hepatitis B or C, HIV, hematological diseases, acute infections, liver disease, renal disease, cancer

Primary outcomes:
measure: Assessment of glucose metabolism using an oral Glucose tolerance test (OGTT) and an intravenous Glucose tolerance test (IVGTT) in pregnant women with a history of bariatric surgery, as well as three to six months after delivery
timeFrame: up to 10 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Unit of Gender Medicine, Medical University of Vienna
name: Alexandra Kautzky-Willer, Univ.Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leutner M, Klimek P, Gobl C, Bozkurt L, Harreiter J, Husslein P, Eppel W, Baumgartner-Parzer S, Pacini G, Thurner S, Kautzky-Willer A. Glucagon-like peptide 1 (GLP-1) drives postprandial hyperinsulinemic hypoglycemia in pregnant women with a history of Roux-en-Y gastric bypass operation. Metabolism. 2019 Feb;91:10-17. doi: 10.1016/j.metabol.2018.10.006. Epub 2018 Nov 15.
Clinical trial NCT03205657: Auto/Allo Tandem Transplant for Relapsed B-NHL
Official title: MAC and autoHSCT, Targeted Immunotherapy and RIC alloHSCT in Children, Adolescents, and Young Adults (CAYA) With Poor-risk Refractory/Relapsed Mature B-NHL: A Retrospective Chart Review
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Hodgkin Lymphoma
Lead sponsor: New York Medical College
Sponsor class: OTHER
First posted: 2017-07-02
Enrollment: 12
Sex: ALL
Minimum age (years): 0
Maximum age (years): 29
Standard ages: CHILD
ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: B-NHL patients who received MAC/AutoSCT and a RIC/AlloSCT

Brief summary: The investigators plan to perform a retrospective review of patients with poor risk relapsed/refractory B-NHL having received HSCT and targeted immunotherapy at the Maria Fareri Children's Hospital between January 1, 2012 and June 1, 2015. The investigators will review the clinical records and collect the data with de-identified medical information from our HSCT clinical research database.

Detailed description: The investigators will obtain the following information from the patient's medical records: clinical factors including age at presentation, gender, clinical presentation, laboratory and pathology data, lymphoma diagnosis, clinical staging criteria, anti-cancer therapy as well as supportive care medicines, complications of therapy (adverse events graded from CTCAE v4.0), and hematopoietic stem cell transplantation therapy (chemotherapy, donor source, cell dose), course (engraftment, GVHD, chimerism), and follow-up (disease status).

Eligibility criteria: Inclusion Criteria:

* This analysis will include all children, adolescents, and young adults less than 29 years old with a histologically confirmed diagnosis of B-NHL treated at the Maria Fareri Children's Hospital

Exclusion Criteria:

* None

Primary outcomes:
measure: Incidence of adverse events related to study treatment (safety)
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: New York Medical College
name: Mitchell Cairo, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gardenswartz A, Mehta B, El-Mallawany NK, van de Ven C, Hochberg J, Flower A, Morris E, Harrison L, Chu Y, Basso J, Gerard P, Islam H, Ayello J, Baxter-Lowe LA, Cairo MS. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2023 Jan;64(1):234-237. doi: 10.1080/10428194.2022.2133542. Epub 2022 Oct 19. No abstract available.
Clinical trial NCT05173948: The Effectiveness of Kinesio Taping in Patients With Chronic Low Back Pain
Official title: Effectiveness of Kinesio Taping and Conventional Physical Therapy in the Management of Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Low-back Pain
Keywords: Low back pain
Chronic
Kinesio taping
TENS
Exercises
Lead sponsor: University of Tabuk
Sponsor class: OTHER
First posted: 2021-12-30
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine the effectiveness of Kinesio taping (KT) with Conventional Physical therapy (CPT) - Transcutaneous Electrical Nerve Stimulation (TENS) and Supervised Exercise therapy and CPT in the management of CLBP.

Detailed description: Chronic low back pain (CLBP) is one of the most common causes of chronic disability which leads to major social and economic consequences. The role and effectiveness of the Kinesio taping (KT) and Conventional Physical therapy (CPT) are evident from the existing literature but no comparison was found on the combination of other physical therapy techniques such as supervised exercise therapy and Transcutaneous Electrical Nerve Stimulation (TENS) with CLBP in the Kingdom of Saudi Arabia

Eligibility criteria: Inclusion Criteria:

* Pain caused by mechanical/nonspecific low back pain.
* Degeneration of the spine and intervertebral disc.
* The visual analog scale of pain 4 and above
* Low back pain for at least three months

Exclusion Criteria:

* Physical therapy treatment is taken in the past 6 months period
* Previous spinal surgery with fixation
* Structural anomalies
* Spinal cord compression
* Severe osteoporosis
* Acute infections
* Severe cardiovascular or metabolic diseases
* Pregnant women

Primary outcomes:
measure: Numerical Pain Rating Scale
timeFrame: Six weeks
measure: Modified Oswestry low back pain disability questionnaire
timeFrame: Six weeks
measure: Lumbar range of motion-Modified Schober test
timeFrame: Six weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tabuk
country: Saudi Arabia
facility: University of Tabuk
state: North West
Study officials:
References:
citation: Pakkir Mohamed SH, Al Amer HS, Nambi G. The effectiveness of Kinesio taping and conventional physical therapy in the management of chronic low back pain: a randomized clinical trial. Clin Rheumatol. 2023 Jan;42(1):233-244. doi: 10.1007/s10067-022-06352-3. Epub 2022 Sep 1.
Clinical trial NCT00075348: Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
Official title: Genetic Mutation Analysis In A VHL Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Cancer
Von Hippel-lindau Syndrome
Keywords: renal cell carcinoma
von Hippel-Lindau syndrome
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-01-12
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: RATIONALE: The identification of gene mutations in individuals who have or are at risk for von Hippel-Lindau syndrome may allow doctors to better determine the genetic processes involved in the development of cancer.

PURPOSE: This genetic study is finding gene mutations in participants with von Hippel-Lindau syndrome or who are at risk for developing von Hippel-Lindau syndrome.

Detailed description: OBJECTIVES:

* Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
* Determine genotype status in these participants.

OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired.

PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053
* Meets 1 of the following criteria:

  * Diagnosis of VHL syndrome
  * At risk of VHL syndrome
  * Family member of patient with VHL syndrome
* VHL syndrome genotype is not known

PATIENT CHARACTERISTICS:

Age

* Adult

Performance status

* Not specified

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
state: Maryland
Study officials:
affiliation: NCI - Urologic Oncology Branch
name: William M. Linehan, MD
role: STUDY_CHAIR
References: